Are miRNAs the key to retinal degeneration?

Article

Absence of a specific RNase III endonuclease in the retina causes no immediate structural abnormalities but does prompt total retinal inactivity, according to a study published in the May 7 2008 issue of the Journal of Neuroscience.

Absence of a specific RNase III endonuclease in the retina causes no immediate structural abnormalities but does prompt total retinal inactivity, according to a study published in the May 7 2008 issue of the Journal of Neuroscience.

Devid Damiani of the Neuroscience Institute, Pisa, Italy and colleagues removed one or both alleles of Dicer, essential for the production and function of mature miRNAs, from the retinas of mice embryos.

The mice with both Dicer alleles removed were born with fully formed retinas that displayed abnormally low electrical activity. By day 16, photoreceptor rosettes had formed; various retinal cell types continued to degenerate and scotopic and photopic responses to electroretinogram (ERG) testing decreased progressively at one, three and five months. Mice with a single allele of Dicer removed registered compromised ERG responses but retinas remained structurally sound throughout life. Retinas with depleted levels of Dicer had lower levels of several different miRNAs.

The researchers concluded that, since removing Dicer prompts gradual retinal degeneration in morphologically correct cells, it is possible that miRNAs are implicated in neurodegenerative disorders.

Related Videos
ARVO 2024: Andrew D. Pucker, OD, PhD on measuring meibomian gland morphology with increased accuracy
 Allen Ho, MD, presented a paper on the 12 month results of a mutation agnostic optogenetic programme for patients with severe vision loss from retinitis pigmentosa
Noel Brennan, MScOptom, PhD, a clinical research fellow at Johnson and Johnson
ARVO 2024: President-elect SriniVas Sadda, MD, speaks with David Hutton of Ophthalmology Times
Elias Kahan, MD, a clinical research fellow and incoming PGY1 resident at NYU
Neda Gioia, OD, sat down to discuss a poster from this year's ARVO meeting held in Seattle, Washington
Eric Donnenfeld, MD, a corneal, cataract and refractive surgeon at Ophthalmic Consultants of Connecticut, discusses his ARVO presentation with Ophthalmology Times
John D Sheppard, MD, MSc, FACs, speaks with David Hutton of Ophthalmology Times
Paul Kayne, PhD, on assessing melanocortin receptors in the ocular space
Osamah Saeedi, MD, MS, at ARVO 2024
© 2024 MJH Life Sciences

All rights reserved.